Aug 17, 2026
The WHO approved the first malaria drug for infants weighing under 5kg, and researchers unveiled a single-dose compound, cabamiquine, showing promise in early trials. Investment in the Medicines for Malaria Venture yielded $13 in health benefits per $1 invested, averting 1.6 million deaths.
Aug 09, 2026
Novartis marks 30 years since its 1996 merger, citing advances in targeted therapy, cell therapy, gene therapy, and malaria. It also named a Levant Country President and won two clinical research awards in Saudi Arabia.
Aug 02, 2026
Federal and international funders have announced life sciences and biotech funding opportunities: NIH awards up to $30 million, NSF fellowships, and roundups exceeding $900 million. Scholarships and grants are open worldwide, with AI and local eligibility as key criteria.
May 29, 2026
Kenya is building local vaccine manufacturing capacity through a WHO-supported mRNA technology transfer project and a three-phase strategy focused on childhood vaccines. The country aims to reduce reliance on imports, with a fill-and-finish facility in Embakasi expected by 2027 and first locally produced vaccines by 2028.
Aug 02, 2026
New research advances sustainable biotechnology: recreating poisonous plant compounds for medicine, a two-step fermentation that removes up to 99% of off-putting smells, and hybrid plants that cut carbon footprints by 62%.
Jul 27, 2026
The Bundibugyo Ebola outbreak in the DRC has surpassed 3,200 cases and 1,400 deaths, becoming the fastest-spreading Ebola outbreak ever. The first-ever Bundibugyo-specific vaccine trial has begun at Oxford, while healthcare workers at the epicenter have gone on strike over unpaid wages. The WHO has declared the outbreak a global health emergency.
Jun 24, 2026
A multicenter EFFORT Trial published in The Lancet Infectious Diseases found that 7-day high-dose primaquine and single-dose tafenoquine significantly reduced P. vivax malaria recurrence compared to the standard 14-day low-dose primaquine regimen. The trial, conducted across Ethiopia, Pakistan, Indonesia, and Cambodia, supports WHO guidelines and potential geographic expansion of tafenoquine use.
Jun 23, 2026
Multiple studies confirm high effectiveness of key antimalarial drugs in Indonesia, Ethiopia, and for malaria prevention in HIV-positive pregnancies. Research shows DHA-PPQ, artemether-lumefantrine, and other treatments remain well-tolerated with no delayed parasite clearance. Findings support continued use of current treatment policies while emphasizing the need for ongoing monitoring.
May 05, 2026
Novartis introduced new long-term social impact and sustainability targets covering access, global health, emissions, waste and water. The plan includes a 2030 access goal and net-zero across the value chain by 2040.
Apr 25, 2026
WHO has prequalified Coartem Baby, the first malaria treatment developed for newborns and young infants weighing 2 to 5 kilograms. The decision opens access through public procurement and donor-funded programs.
Mar 29, 2026
Australia's National Health and Medical Research Council marks 90 years of funding medical breakthroughs while facing warnings that research institutes could exhaust capital within a decade. The NHMRC's success includes funding the HPV vaccine that put Australia on track to eliminate cervical cancer by 2035, but sustained funding is needed to maintain world-class research capabilities.
Mar 28, 2026
India launches ₹10,000 crore Biopharma SHAKTI initiative to transform from generics manufacturing to innovation-led biologics leadership. The national mission aims to capture 5% of global biopharmaceutical market while addressing structural challenges in drug discovery and AI adoption.
Feb 14, 2026
Three new computational approaches enhance molecular property prediction and drug design through advanced neural networks, multimodal learning, and thermodynamic analysis of receptor-ligand interactions.
Feb 13, 2026
Isomorphic Labs introduced IsoDDE, a drug discovery engine that outperforms AlphaFold 3 by a factor of two in prediction accuracy. Google also updated Gemini 3 Deep Think, which now outperforms competing models in complex scientific tasks.
Feb 13, 2026
California-based Centivax has begun dosing participants in a Phase 1A clinical trial of Centi-Flu 01, a universal influenza vaccine designed to target conserved viral regions across all flu strains. Initial data from approximately 180 participants is expected within the year.